# Association between genotypes of ABCB1, ABCG2 and CYP3A5 and the risk of

# atrial fibrillation

<u>Tzu-Yu Pan</u><sup>a</sup>, Tzu-Yen Lin<sup>b</sup>, Wei-Chung Tsai<sup>c,d\*</sup>, Ming-Tsang Wu<sup>a,b,e,\*</sup>

<sup>a</sup>Ph.D. Program in Environmental and Occupational Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
<sup>b</sup>Department of Public Health, College of Health Sciences, Kaohsiung Medical University, Kaohsiung, Taiwan
<sup>c</sup>Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
<sup>d</sup>Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
<sup>e</sup>Department of Family Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

Running title: *ABCB1*, *ABCG2*, *CYP3A5* and atrial fibrillation risk

### **Corresponding authors:**

Dr. Wei-Chung Tsai, MD, E-mail: <u>k920265@gap.kmu.edu.tw</u> Dr. Ming-Tsang Wu, MD, ScD E-mail: <u>e\_encourage@yahoo.com</u>; <u>960021@cc.kmuh.org.tw</u>

# **ORCID:**

Tzu-Yu Pan, <u>orcid.org/0000-0003-3005-1944</u> Tzu-Yen Lin, <u>orcid.org/0009-0009-6310-2323</u> Wei-Chung Tsai, <u>orcid.org/0000-0002-1123-6954</u> Ming-Tsang Wu, <u>orcid.org/0000-0001-7307-7816</u>

# 1 Abstract

# 2 Background:

3 Atrial fibrillation (AF) is a prevalent clinical condition worldwide, with a high global incidence that

- 4 significantly impacts disease burden and mortality rates. Single nucleotide polymorphisms in
- 5 *ABCB1*, *ABCG2* and *CYP3A5* are common, but the clinical outcomes are poorly understood. This
- 6 study examines the association between the genetic variations of *ABCB1*, *ABCG2* and *CYP3A5* and
- 7 the risk of AF in a Taiwanese population.
- 8

# 9 Methods:

10 This case-control study recruited 216 AF patients from two hospitals in Taiwan between 2021 and

11 2023. Control groups were matched by age (± one year), gender, and AF-related variables from the

Taiwan Biobank. Logistic regression analyzed the association between three genetic variants andAF risk.

14

# 15 **Results:**

16 A significant association was noted between *ABCG2 rs2231142* and AF risk. Those with *ABCG2* 17 *rs2231142 G/T* and *T/T* genotypes had a 1.91-fold (95% CI = 1.04-3.53) increased risk of AF 18 compared to those with the G/G genotype. This association was particularly pronounced in males in 19 those carrying *ABCG2 rs2231143 T/T* genotype having a 4.47-fold (95% CI = 1.02-19.67) increased 12 risk after adjusting for covariates. There were no overall significant associations between AF risk 21 and the polymorphisms of *ABCB1 rs4148738* and *rs1128503*, nor *CYP3A5 rs776746*.

22

# 23 Conclusion:

A robust risk association between the *ABCG2 rs2231142 T allele* and AF in Asian populations,
particularly in male adults, suggests that genetic testing for this polymorphism could be integrated
into risk assessment models for AF.

27

28 Keywords: Single nucleotide polymorphisms, Atrial fibrillation, *ABCB1*, *ABCG2*, *CYP3A5* 

- 29
- 30

1000Genomes	1000 Genomes Project						
AF	Atrial fibrillation						
ABCB1	Adenosine triphosphate binding cassette subfamily B member 1						
ABCG2	ATP-binding cassette subfamily G member 2						
ATPase	Adenosine triphosphatase						
BCRP	Breast cancer resistance protein						
CYP3A5	Cytochrome P450 family 3 subfamily A member 5						
CYP450	Cytochrome P450 proteins						
DOACs	Direct oral anticoagulants						
GBD 2017	Global Burden of Disease Study 2017						
gnomAD	Genome Aggregation Database						
GWAS	Genome-Wide Association Studies						
HbA1C	Glycated hemoglobin						
IRB	Institutional Review Board						
KMUH	Kaohsiung Medical University Hospital						
КМТТН	Kaohsiung Municipal Ta-Tung Hospital						
LDL	Low-density lipoprotein cholesterol						
MYOZ1	Myozenin 1						
P-gp	P-glycoprotein						
PITX2	Paired like homeodomain 2						
SNPs	Single Nucleotide Polymorphisms						
TG	Triglyceride						
TWB	Taiwan Biobank						
ZFHX3	Zinc finger homeobox 3						

# 31 Nonstandard Abbreviations and Acronyms

32

33

#### 35 Introduction

36 Atrial fibrillation (AF) is recognized globally as a prevalent clinical condition that elevates the risk of systemic thromboembolism, heart failure, stroke, dementia and mortality, significantly 37 impacting disease burden and mortality rates worldwide. <sup>1,2</sup> Current estimates indicate that 38 approximately 33 million people are affected by AF globally, demonstrating its extensive reach and 39 the urgency for comprehensive understanding and effective management strategies.<sup>3</sup> The 40 41 prevalence of AF differs markedly between genders, with rates of 1.4% in males and 0.7% in 42 females. Additionally, incidence rates are reported at 1.68 per 1000 males and 0.76 per 1000 females, highlighting a substantial gender disparity in AF occurrence. <sup>1,2</sup> Age also plays a crucial 43 role, with the Global Burden of Disease Study 2017 (GBD 2017) revealing that AF prevalence 44 45 increases with age—from 0.07% among those aged 30 to 34, to 8.18% for those aged 95 and above. 46

47 Reports have also suggested potential disparities in the incidence and characteristics of AF across different racial and ethnic groups.<sup>5-7</sup> In Taiwan, heart disease, primarily driven by AF, ranks 48 as the leading cause of death in individuals aged 65 and above and the second leading cause of 49 50 death overall, following cancer, according to the 2021 national mortality statistics from the Ministry of Health and Welfare.<sup>2</sup> Extensive research has been directed towards unraveling the mechanisms 51 underlying AF. Predominantly, AF is seen as a consequence of diseases such as hypertension, 52 ischemic and structural heart disease, which contribute to the electrical and structural remodeling of 53 the atria.<sup>8-10</sup> Despite the known risk factors such as advancing age, heart disease, elevated blood 54 55 pressure and excessive alcohol consumption, a significant number of cases occur without 56 identifiable risk factors, hinting at a potential genetic predisposition to AF. This gap in understanding limits the development of effective treatments and highlights the necessity for further 57 investigation, particularly in the realm of precision medicine.<sup>2,11</sup> 58

59 Over 60% of AF variability is attributed to genetic factors heightening AF susceptibility, 60 influencing AF development and maintenance. <sup>12-14</sup> Genetic variations in the genes *ABCB1* 61 (*adenosine triphosphate (ATP) binding cassette subfamily B member 1)*, *ABCG2 (ATP-binding* 

cassette subfamily G member 2), and CYP3A5 (cytochrome P450 family 3 subfamily A member 5), 62 63 responsible for encoding P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) and cytochrome P450 proteins (CYP450) respectively, play a significant role in altering transporter 64 function. These genetic variations impact crucial aspects of AF, including cardiac electrical 65 conduction, ion channel function and structural remodeling.<sup>15,16</sup> Studies have found specific single 66 nucleotide polymorphisms (SNPs) such as rs1128503 and rs4148738 in ABCB1, which modify P-gp 67 68 expression; furthermore, ABCG2 rs2231142 G>T genotype has been linked to decreased BCRP <sup>17,18</sup> while CYP3A5 is crucial in metabolizing anticoagulants and 69 protein expression, stroke-prevention drugs, and this process significantly impacts the achievement of appropriate 70 anticoagulation levels in patients with AF.<sup>19</sup> 71

72 Understanding the relationship between these genetic variants and the risk of developing AF is 73 essential as it can provide insight into underlying molecular mechanisms and potentially guide the development of targeted therapies in the era of precision medicine.<sup>20</sup> In recent years, precision 74 medicine has garnered increasing attention, emphasizing the significant relationship between 75 diseases and genes. <sup>21</sup> Each individual possesses a unique genome that can influence their disease 76 susceptibility, treatment response and drug metabolism, <sup>22</sup> and through genetic testing and analysis, 77 researchers can establish correlations between genetic variants and particular diseases. <sup>23</sup> This 78 knowledge can predict an individual's disease risk, facilitate accurate disease diagnosis, and aid in 79 selecting the most suitable treatment options; <sup>24</sup> however, the current understanding of the 80 relationship between these gene variants and the risk of AF remains unclear. In this study, we aimed 81 to investigate the association between genetic variants of ABCB1 (rs1128503, rs4148738), ABCG2 82 (rs2231142) and CYP3A5 (rs776746), and the risk of AF. 83

84

#### 85 Materials and methods

### 86 Study subjects

87 This is an ongoing case-control study. The case patients diagnosed as AF by board-certified
88 cardiologists were recruited from Kaohsiung Medical University Hospital (KMUH) and Kaohsiung

89 Municipal Ta-Tung Hospital (KMTTH) between January 2021 and January 2023. The study 90 subjects included individuals aged 20-85 years and willing to cooperate with blood-draw procedures. Patients undergoing cancer treatment, those with impaired renal function (eGFR<15 ml/min/1.73 91  $m^2$ ) and those who could not cooperate were excluded from the study. After the written informed 92 consent was received, a designated researcher administered a standardized and structured 93 94 questionnaire and reviewed the medical charts to collect age, gender, history of hypertension and 95 diabetes and blood test data such as glycated hemoglobin (HbA1C), serum creatinine, triglyceride 96 (TG) and low-density lipoprotein cholesterol (LDL)). A total of 216 AF patients were enrolled in the study period. 97

98 Potential healthy controls were selected from the Taiwan Biobank (TWB) cohort, a 99 community-based cohort comprising healthy adults recruited from all over Taiwan. The TWB 100 cohort, established in 2005, aimed to collect genetic and medical information from 200,000 ethnic 101 Taiwanese individuals aged 20 years or above without a history of cancer, where this cohort 102 underwent comprehensive data collection including questionnaires, physical examinations and 103 biochemical tests on blood and urine samples, and has continued to collect biological samples 104 to-date, including DNA, blood plasma and urine from study subjects, which can be provided to 105 researchers in Taiwan for study purposes at a minimal cost. As of 2020, the TWB cohort had 106 enrolled 122,068 potential study adults aged 30-75 years with baseline data. The Institutional 107 Review Board (IRB) of KMUH approved this study.

Among the 216 AF patients, 185 subjects have provided blood samples for genotyping results. In addition, in order to match the AF patients of similar age with healthy controls from TWB cohort, we further excluded 44 patients aged over 76 years and left 141 eligible cases in the study (**Figure** 1). Then, the case patients were matched with the controls (1: 1 ratio) based on age within a range of  $\pm 1$  year and the same gender from TWB cohort with specific genotypes of *ABCB1 (rs1128503, rs4148738), ABCG2 (rs2231142),* and *CYP3A5 (rs776746)* (n = 108,829). The final study subjects were 141 AF cases and 141 healthy controls.

115

#### 116 Genotyping of ABCB1 (rs1128503, rs4148738), ABCG2 (rs2231142) and CYP3A5 (rs776746)

#### 117 polymorphisms from the case study group

The QIAamp DNA Mini Kit (Qiagen, Germany) was used to extract genomic DNA from peripheral blood samples collected from patients in the case study group, following the manufacturer's instructions, while TaqMan probes designed explicitly for standardized SNPs assays (Thermo Fisher Scientific, Inc) were employed to assess single nucleotide polymorphic variations in the *ABCB1* (rs1128503, rs4148738), *ABCG2* (rs2231142) and *CYP3A5* (rs776746) genes. Probe IDs and SNPs regions are listed in **Table S1**.

For SNPs genotyping, a reaction mixture containing 10 µL was prepared, containing 10 ng of 124 125 genomic DNA, 2X TaqMan® Master Mix, 20X Assay Working Stock probe and nuclease-free water. A negative control (no template) was included in the experiment. The cycling conditions adhered to 126 127 the manufacturer's standard protocol as recommended where real-time PCR was conducted on all 128 samples using the QuantStudio 3 instrument (Applied Biosystems) and QuantStudio<sup>™</sup> Design & 129 Analysis Software was employed to analyze the data and identify homozygous and heterozygous 130 alleles. To ensure the reliability of the genotyping assays, approximately 9.4% of patients (n = 131 15/141) were randomly selected for the genotyping of each polymorphism; this additional step 132 being performed to validate the consistency and accuracy of the genotyping results. The reaction of 133 PCR for direct sequencing is shown in Supplemental Material and Table S2 that was also performed to confirm the genotyping results (Figure S1). For TWB cohorts, we extracted the 134 135 genotype information of ABCB1 (rs1128503, rs4148738), ABCG2 (rs2231142), and CYP3A5 (rs776746) genes from Genome-Wide Genotyping: Affymetrix Axiom TWB and TWB 2.0 database, 136 137 in which genotype analysis was either from the Axiom Genome-Wide TWB array or Axiom Genome-Wide TWB 2.0 array.<sup>25</sup> 138

139

### 140 Statistical analysis

The frequencies of *ABCB1* (*rs1128503*), *ABCG2* (*rs2231142*) and *CYP3A5* (*rs776746*)
genotypes were assessed for Hardy-Weinberg disequilibrium in the TWB-1 control group (n = 141).

143 A comparison of demographic characteristics and genotypes between the case group (n = 141) and 144 the TWB-1 control group (n = 141) was performed. Logistic regression models were employed to investigate the impact of ABCB1 (rs1128503, rs4148738), ABCG2 (rs2231142), and CYP3A5 145 (rs776746) genotypes on AF risk, both before and after adjusting for covariates, including age 146 147 (continuous variables), gender, diabetes, hypertension, HbA1C, serum creatinine, TG and LDL. 148 Odds ratios (OR), confidence intervals (CI) and p-values were calculated and presented. If both 149 ABCB1 (rs1128503, rs4148738), ABCG2 (rs2231142) and CYP3A5 (rs776746) genotypes showed 150 significant differences between case patients and controls, the combined effect of both genes was 151 further examined. These analyses were also stratified by gender. All statistical analyses were 152 conducted using IBM SPSS Statistics 25 software.

153

#### 154 **Results**

#### 155 Characteristics of the Study Population

156 The demographic characteristics of 141 AF patients and the 141 TWB-1 controls are shown in Table 1. Among these 141 AF patients, 48 (34.0%) were female and 93 (66.0%) were male, while 157 158 the percentages of gender, age group (40-60 and > 60 years) and educational levels were identical in 159 AF patients and TWB-1 controls. Additionally, between the two groups of AF patients and TWB-1 160 controls, the aforementioned variables (gender, age groups and other variables including diabetes, hypertension, HbA1c, serum creatinine, TG and LDL) were not significantly different (all p > 0.05). 161 162 Of the 141 AF patients, 24.8% had diabetes and 35.5% had hypertension; additionally, the HbA1c 163 level (6.2%) was higher than the normal range of 4.0-5.6%.

164

#### 165 Allele frequencies in TWB cohort

The prevalence of *ABCB1 rs1128503 A/A*, *A/G*, and *G/G* was 41.8%, 46.8% and 11.3% respectively, for TWB-1 (n = 141). For *ABCB1 rs4148738 T/T*, *C/T*, and *C/C*, the prevalence was 34.0%, 41.8% and 24.1% respectively, for TWB-1. *ABCG2 rs2231142 G/G*, *G/T*, and *T/T* were 59.6%, 33.3% and 7.1% respectively, in TWB-1. *CYP3A5 rs776746 C/C*, *T/C*, and *T/T* were 46.1%,

44.0% and 9.9% respectively, in TWB-1 (**Table S3**). All frequencies of *ABCB1 (rs1128503, rs4148738)*, *ABCG2 (rs2231142)*, and *CYP3A5 (rs776746)* genotypes in TWB-1 were consistent with the statistics of the Hardy-Weinberg equilibrium, which were insignificant (p > 0.05) (**Table S3**).

174

### 175 Association of ABCB1, ABCG2 and CYP3A5 polymorphisms

**Table 2** shows the association of *ABCB1 (rs1128503, rs4148738), ABCG2 (rs2231142),* and *CYP3A5 (rs776746)* genotypes with AF risk before and after adjusting for other covariates (including diabetes, hypertension, HbA1c, serum creatinine, TG and LDL). Genotypes of *ABCG2 rs2231142 G/T* and *T/T* exhibited a significant risk of developing AF compared to *G/G* genotypes after adjusting for other covariates (AOR = 1.912, 95% CI = 1.035-3.53), although no significant difference was observed in the other three SNPs after adjustment.

Categorized by sex, the significant effect of ABCG2 rs2231143 remained present in males but 182 183 not females, likely due to the small sample size of female AF patients (n = 48) (**Table 3**). Males 184 with the combined genotypes of ABCG2 rs2231143 G/T and T/T had a significant risk of AF when 185 compared with males carrying ABCG2 rs2231143 G/G genotype (crude OR=2.005, 95% 186 CI=1.118-3.596; AOR=2.179, 95% CI=0.894-5.307). There was also a trend toward statistical 187 significance for the association between male subjects and AF (p = 0.021 and 0.041 before and after 188 adjusting for other covariates), suggesting a potential risk factor associated with this haplotype in 189 males.

190

#### 191 Discussion

192 This hospital-based case-control study underscores the importance of the *ABCG2 rs2231142 G/T* 193 and *T/T* genotypes, which exhibit a higher risk of developing AF than those with the G/G genotype, 194 particularly among male patients. However, no associations were identified between the 195 polymorphisms of *ABCB1 rs4148738* and *rs1128503*, and *CYP3A5 rs776746* genotypes and AF 196 risk.

*ABCG2* belongs to a superfamily of 48 human ATP-binding cassette transporters, which
typically facilitate the transport of various substrates and rely on ATP-binding for activation. The *ABCG2 rs2231142* variant results in a substitution of glutamine with lysine (Q141K) in exon 5.
Previous studies have reported that individuals carrying the *ABCG2 rs2231142* variant (*G/T* and *T/T*)
exhibit significantly lower levels of ABCG2 protein within red blood cells as well as reduced
ABCG2 adenosine triphosphatase (ATPase) activity compared to those with the *G/G* genotype.

203 The presence of the ABCG2 rs2231142 T allele leads to an approximately 50% reduction in ABCG2 protein expression. <sup>26</sup> Zhang et al. found that variations in the ABCG2 rs2231142 variant 204 could impact the serum levels of pro-inflammatory and pro-angiogenic markers in chronic 205 inflammatory arterial conditions, hinting at a correlation between inflammation and the ABCG2 206 rs2231142 variant. <sup>27</sup> These findings suggest that ABCG2 rs2231142 could play a crucial 207 208 physiological role as an excreter of environmental and endogenous toxins, and it might influence 209 the multidrug transporter function in human erythrocytes, corresponding to pharmacologically relevant genetic variations.<sup>28</sup> Furthermore, recent studies have emphasized that the 210 pharmacogenetic implications of these findings could connote the efficacy of direct oral 211 212 anticoagulants (DOACs) being enhanced, as genetic variants influence drug metabolism and response. 29,30 213

In recent years, DOACs such as apixaban, dabigatran, edoxaban and rivaroxaban have 214 215 replaced vitamin K antagonists for treating AF due to their ease of use and better effectiveness. In a rat model of pharmacokinetic interaction, almonertinib significantly increased systemic exposure to 216 apixaban and rivaroxaban by inhibiting ABCB1 and ABCG2. <sup>31</sup> Previous studies have shown 217 218 variable results regarding the relationship between genotypes and DOACs in AF patients. Gulilat et 219 al. reported that the ABCG2 rs2231142 T allele predicted higher concentrations of apixaban in Caucasian AF patients, <sup>32</sup> but was associated with a lower concentration and lower oral clearance of 220 apixaban in Japanese AF patients.<sup>33,34</sup> Additionally, no correlations were observed between the 221 ABCG2 rs2231142 and rivaroxaban concentrations in Japanese AF patients. <sup>35</sup> Nevertheless, we 222 223 observed a significant increase in the risk of AF associated with the ABCG2 rs2231142 T allele in

patients treated with rivaroxaban (Table S4), indicating that this SNPs might affect the drug
 transporters and metabolism of DOACs, making additional studies necessary to clarify the role of
 this SNPs in DOACs pharmacokinetic interactions.

227 Previous studies have shown that the loss-of-function ABCG2 rs2231142 T allele is associated with hyperuricemia, which might contribute to vascular damage and cardiovascular diseases such as 228 atrial fibrillation, coronary artery disease, heart failure and stroke. <sup>36-38</sup> Similar observations were 229 230 noted in an earlier prospective cohort study conducted in Taiwan, where hyperuricemia emerged as 231 an independent risk factor for mortality from all causes, total cardiovascular disease and ischemic stroke.<sup>39</sup> In other studies, it is also suggested that the effect size of the ABCG2 rs2231142 is more 232 significant in males. <sup>36,40,41</sup> Our current data showed a similar interaction, as we found a significant 233 234 association between the rs2231142 T allele and AF risk in males, which was consistent with these Asian population studies, <sup>36-41</sup> and although previous studies have demonstrated that estrogen levels 235 could affect ABCG2 expression, <sup>42,43</sup> this might explain why we observed the association with atrial 236 237 fibrillation risk predominantly in males rather than females.

238 Currently, no studies have examined the AF risk linked to the ABCG2 rs2231142 genotype, but 239 research on other SNPs regarding AF risk has been conducted. Genetic factors contributing to AF 240 are gaining more attention, with estimates of heritability reaching 22% in the UK Biobank and 62% in a twin study conducted in Denmark.<sup>14,44</sup> Daniel et al. were the first to report the Genome-wide 241 242 association studies (GWAS) for AF, where the upstream region of the transcription factor gene PITX2 on 4q25 was significantly associated with AF.<sup>45</sup> Several other genetic loci related to AF 243 have been identified, including variants in or near ZFHX3 (Zinc Finger Homeobox 3), PITX2 244 (paired like homeodomain 2), and MYOZ1 (myozenin 1), which show the most associations.<sup>46</sup> 245

Our research further highlights the significant relationship between the *ABCG2 rs2231142 T* allele and increased AF risk, particularly in males. This suggests that integrating genetic testing for this polymorphism into risk assessment models for AF could enhance precision in AF management strategies, especially in populations with a high prevalence of this risk allele. Past studies have primarily focused on pharmacogenomics or the risk of cardiovascular and hyperuricemia. <sup>36-41</sup> The association between polymorphisms of *ABG2 rs2231142* genotypes and AF subjects might result from the influence of hyperuricemia, obesity, hypertension and dyslipidemia, as well as sex differences caused by estrogen levels, or both. <sup>47</sup> In the study conducted by Doshi et al., <sup>48</sup> *ABCG2* expression was examined in male obesity mice. The findings indicated elevated levels of *ABCG2* protein, suggesting a potential association between increased *ABCG2* expression and obesity-related AF, although the mechanism of the influence of the *ABCG2 rs2231142* locus on the risk effect of developing AF still needs to be investigated.

258 Table S5 shows the similar variant allele frequencies of ABCB1, ABCG2 and CYP3A5 genotypes in East Asians from different databases and from the datasets of TWB, suggesting the 259 260 robustness of target genotype frequencies in the public-domain databases. The 1000 Genomes Project (1000Genomes) and the Genome Aggregation Database (gnomAD) are public websites that 261 262 respectively encompass data from more than 2,500 individuals representing global populations and 263 aggregate over 800,000 exome and whole-genome sequences from seven ethnic groups, sharing 264 summary data with the scientific community (https://www.internationalgenome.org/ and 265 https://reurl.cc/RWnZzg, accessed on 2024/4/18). The TWB is an ongoing prospective study that 266 involves over 200,000 individuals aged 20-70 in Taiwan.

267 The distributions of genotype and allelic frequencies in Taiwan and other populations such as 268 American, European, African, South Asian, Central Asian and East Asian are summarized in Table S6. The distributions of allelic frequencies in other populations were taken from the database of 269 270 NCBI (https://www.ncbi.nlm.nih.gov/, assessed on 2024/4/18). The ABCB1 rs1128503 G allele and 271 rs4148738 T allele have a higher prevalence among Africans, with frequencies of 80% and 77% 272 respectively, while the ABCG2 T allele is more common in American, East Asian and Taiwanese populations consistent with the findings reported by Alrajeh et al.<sup>49</sup> Their reports noted that the 273 frequency of the allele associated with reduced ABCG2 function is exceptionally high among 274 Asians while the frequency of the CYP3A5 C allele is lower in African populations, with a 275 276 frequency of 31%; interestingly, the prevalence of the ABCG2 T allele is higher in East Asian, 277 Taiwanese and American populations (29.8%, 31.5% and 22.5%, respectively) compared to

European, South Asian and African populations (9.8%, 9% and 2.6%, respectively). These
differences may be attributed to factors such as database sources, study designs and ethnicities.

280

# 281 Conclusion

In conclusion, the findings suggest a strong association between the *ABCG2 rs2231142 T* allele and a higher risk of AF among Taiwanese male subjects, with a 4.5-fold higher risk compared to controls, and a 1.9-fold risk when combining *ABCG2* genotypes in the overall population. However, no significant associations were identified between the polymorphisms of *ABCB1 rs4148738* and *rs1128503*, as well as *CYP3A5 rs776746* genotypes and AF risk. Further studies with larger sample sizes are necessary to investigate the interaction of the *ABCG2 rs2231142* genotype with AF risk.

### 289 Acknowledgment

290 Not applicable.

291

### 292 Sources of Funding

293 This work was supported by grants from Kaohsiung Medical University Hospital (KMUH108-8R71), Kaohsiung Medical University Research Center Grant (KMU-TC108A01), 294 295 from the Integrative Project of National Health Research Institutes and Kaohsiung Medical 296 University (NHRIKMU-111-I005), Ministry Science Technology of and (MOST 297 108-2638-B-037-001-MY2).

298

# 299 Disclosures

The authors declare that they have no known competing financial interests or personal relationshipsthat could have appeared to influence the work reported in this paper.

302

# 303 Authors' contributions

Tzu-Yen Lin was responsible for Methodology, Validation, Investigation, Data curation; Tzu-Yu
 Pan was responsible for Methodology, Validation, Formal analysis, Resources, Data curation,
 Writing – original draft and Writing- Reviewing and Editing; Wei-Chung Tsai were responsible for
 Data Curation and Resources, Writing-Review and editing; Ming-Tsang Wu was responsible for
 Conceptualization, Writing-Review and editing, Supervision, Project administration, Funding
 acquisition.

310

### 311 Availability of data and materials

The data are not publicly available due to the nature of information that could compromise theprivacy of research participants.

314

# 315 Ethics approval and consent to participate

316 The study design was approved by the institutional review board of Kaohsiung Medical University

- 317 Hospital (KMUHIRB-G(I)-20200040).
- 318

# 319 Supplemental Material

- 320 Supplemental Method
- 321 Tables S1–S6
- **322** Figure S1
- **323** References <sup>50</sup>
- 324

# 325 **References**

- Chien K-L, Su T-C, Hsu H-C, Chang W-T, Chen P-C, Chen M-F, Lee Y-T. Atrial fibrillation
   prevalence, incidence and risk of stroke and all-cause death among Chinese. *International journal of cardiology*. 2010;139:173-180. doi: 10.1016/j.ijcard.2008.10.045
- 329 2. Andersen JH, Andreasen L, Olesen MS. Atrial fibrillation—a complex polygenetic disease.
  330 *European Journal of Human Genetics*. 2021;29:1051-1060. doi:
  331 10.1038/s41431-020-00784-8
- Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C,
   Lubitz SA, Magnani JW, Ellinor PT. 50 year trends in atrial fibrillation prevalence,
   incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. *The Lancet*. 2015;386:154-162. doi: 10.1016/S0140-6736(14)61774-8
- Melki S, Salem B, Soulimane A, Serhier Z, Dahdi S. Profile and evolution of the Global
  Burden of Morbidity in the Maghreb (Tunisia, Morocco, Algeria). The Triple burden of
  morbidity. *La Tunisie Medicale*. 2018;96:760-773.
- 339 5. Zhang J, Johnsen SP, Guo Y, Lip GY. Epidemiology of atrial fibrillation:
  340 geographic/ecological risk factors, age, sex, genetics. *Cardiac electrophysiology clinics*.
  341 2021;13:1-23. doi: 10.1016/j.ccep.2020.10.010
- 342 6. Nanda A, Kabra R. Racial differences in atrial fibrillation epidemiology, management, and
  343 outcomes. *Current Treatment Options in Cardiovascular Medicine*. 2019;21:1-11. doi:
  344 10.1007/s11936-019-0793-5
- Tamirisa KP, Al-Khatib SM, Mohanty S, Han JK, Natale A, Gupta D, Russo AM, Al-Ahmad
  A, Gillis AM, Thomas KL. Racial and ethnic differences in the management of atrial
  fibrillation. *CJC open*. 2021;3:S137-S148. doi: 10.1016/j.cjco.2021.09.004
- Šihák R, Haman L, Táborský M. 2016 ESC Guidelines for the management of atrial
   fibrillation developed in collaboration with EACTS. *Cor et vasa*. 2016;6:e636-e683. doi:
   10.1093/eurheartj/ehw210
- Gudbjartsson DF, Holm H, Sulem P, Masson G, Oddsson A, Magnusson OT,
   Saemundsdottir J, Helgadottir HT, Helgason H, Johannsdottir H. A frameshift deletion in the
   sarcomere gene MYL4 causes early-onset familial atrial fibrillation. *European heart journal*.
   2016:ehw379. doi: 10.1093/eurheartj/ehw379
- Nattel S. Molecular and cellular mechanisms of atrial fibrosis in atrial fibrillation. *JACC: Clinical Electrophysiology*. 2017;3:425-435. doi: 10.1016/j.jacep.2017.03.002
- Baturina O, Chashkina M, Andreev D, Mirzaev K, Bykova A, Suvorov A, Yeryshova D,
  Suchkova S, Sychev D, Syrkin A. Pharmacokinetic and Pharmacogenetic Predictors of
  Major Bleeding Events in Patients with an Acute Coronary Syndrome and Atrial Fibrillation
  Receiving Combined Antithrombotic Therapy. *Journal of Personalized Medicine*.
  2023;13:1371. doi: 10.3390/jpm13091371
- Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF,
  Kim Y-H, McAnulty Jr JH, Zheng Z-J. Worldwide epidemiology of atrial fibrillation: a
  Global Burden of Disease 2010 Study. *Circulation*. 2014;129:837-847. doi:

### 365 10.1161/CIRCULATIONAHA.113.005119

- Ishikawa K, Hajjar RJ. Current methods in cardiac gene therapy: overview. *Cardiac Gene Therapy: Methods and Protocols*. 2017:3-14. doi: 10.1007/978-1-4939-6588-5\_1
- 368 14. Christophersen IE, Ravn LS, Budtz-Joergensen E, Skytthe A, Haunsoe S, Svendsen JH,
  369 Christensen K. Familial aggregation of atrial fibrillation: a study in Danish twins.
  370 *Circulation: Arrhythmia and Electrophysiology.* 2009;2:378-383. doi:
  371 10.1161/CIRCEP.108.786665
- 372 Lubitz SA, Lunetta KL, Lin H, Arking DE, Trompet S, Li G, Krijthe BP, Chasman DI, 15. 373 Barnard J, Kleber ME. Novel genetic markers associate with atrial fibrillation risk in Journal 374 Europeans and Japanese. of the American College of Cardiology. 375 2014;63:1200-1210. doi: 10.1016/j.jacc.2013.12.015
- 376 16. Christophersen IE, Ellinor PT. Genetics of atrial fibrillation: from families to genomes.
   377 *Journal of human genetics*. 2016;61:61-70. doi: 10.1038/jhg.2015.44
- 378 17. Gong IY, Mansell SE, Kim RB. Absence of both MDR 1 (ABCB 1) and Breast Cancer
  379 Resistance Protein (ABCG 2) Transporters Significantly Alters Rivaroxaban Disposition and
  380 Central Nervous System Entry. *Basic & clinical pharmacology & toxicology*.
  381 2013;112:164-170. doi: 10.1111/bcpt.12005
- Mizuno T, Fukudo M, Fukuda T, Terada T, Dong M, Kamba T, Yamasaki T, Ogawa O,
  Katsura T, Inui K-i. The effect of ABCG2 genotype on the population pharmacokinetics of
  sunitinib in patients with renal cell carcinoma. *Therapeutic drug monitoring*.
  2014;36:310-316. doi: 10.1097/FTD.00000000000025
- Sychev DA, Sokolov AV, Reshetko OV, Fisenko VP, Sychev IN, Grishina EA, Bochkov PO,
  Shevchenko RV, Abdullaev SP, Denisenko NP. Influence of ABCB1, CYP3A5 and CYP3A4
  gene polymorphisms on prothrombin time and the residual equilibrium concentration of
  rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice. *Pharmacogenetics and Genomics*. 2022;32:301-307. doi: 10.1097/FPC.000000000000483
- 391 20. Sinner MF, Ellinor PT, Meitinger T, Benjamin EJ, Kääb S. Genome-wide association studies
  392 of atrial fibrillation: past, present, and future. *Cardiovascular research*. 2011;89:701-709.
  393 doi: 10.1093/cvr/cvr001
- 394 21. König IR, Fuchs O, Hansen G, von Mutius E, Kopp MV. What is precision medicine?
  395 *European respiratory journal*. 2017;50. doi: 10.1183/13993003.00391-2017
- Ramaswami R, Bayer R, Galea S. Precision medicine from a public health perspective. *Annual Review of Public Health*. 2018;39:153-168. doi:
  10.1146/annurev-publhealth-040617-014158
- 399 23. Robinson PN. Deep phenotyping for precision medicine. *Human mutation*. 2012;33:777-780.
  400 doi: 10.1002/humu.22080
- 401 24. McGrath S, Ghersi D. Building towards precision medicine: empowering medical
  402 professionals for the next revolution. *BMC medical genomics*. 2016;9:1-6. doi:
  403 10.1186/s12920-016-0183-8
- 404 25. Feng Y-CA, Chen C-Y, Chen T-T, Kuo P-H, Hsu Y-H, Yang H-I, Chen WJ, Su M-W, Chu

- H-W, Shen C-Y. Taiwan Biobank: A rich biomedical research database of the Taiwanese
  population. *Cell Genomics*. 2022;2. doi: 10.1016/j.xgen.2022.100197
- 407 26. Dong Z, Guo S, Yang Y, Wu J, Guan M, Zou H, Jin L, Wang J. Association between ABCG
  408 2 Q141K polymorphism and gout risk affected by ethnicity and gender: a systematic review
  409 and meta-analysis. *International journal of rheumatic diseases*. 2015;18:382-391. doi:
  410 10.1111/1756-185X.12519
- Zhang D, Ding Y, Wang X, Xin W, Du W, Chen W, Zhang X, Li P. Effects of ABCG2 and
  SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and
  diabetes mellitus treated with rosuvastatin. *European journal of clinical pharmacology*.
  2020;76:939-946. doi: 10.1007/s00228-020-02882-4
- Cleophas M, Joosten L, Stamp LK, Dalbeth N, Woodward OM, Merriman TR. ABCG2
  polymorphisms in gout: insights into disease susceptibility and treatment approaches. *Pharmacogenomics and personalized medicine*. 2017:129-142. doi: 10.2147/PGPM.S105854
- 419 29. Kim H, Song T-J, Yee J, Kim D-H, Park J, Gwak HS. ABCG2 gene polymorphisms may
  420 affect the bleeding risk in patients on apixaban and rivaroxaban. *Drug Design, Development*421 *and Therapy*. 2023:2513-2522. doi: 10.2147/DDDT.S417096
- 30. Nakagawa J, Kinjo T, Aiuchi N, Ueno K, Tomita H, Niioka T. Impacts of pregnane X
  receptor and cytochrome P450 oxidoreductase gene polymorphisms on trough
  concentrations of apixaban in patients with non-valvular atrial fibrillation. *European Journal of Clinical Pharmacology*. 2023;79:127-135. doi: 10.1007/s00228-022-03424-w
- Wang Z, Li Y, He X, Fu Y, Li Y, Zhou X, Dong Z. In vivo evaluation of the pharmacokinetic
  interactions between almonertinib and rivaroxaban, almonertinib and apixaban. *Frontiers in Pharmacology*. 2023;14:1263975. doi: 10.3389/fphar.2023.1263975
- Gulilat M, Keller D, Linton B, Pananos AD, Lizotte D, Dresser GK, Alfonsi J, Tirona RG,
  Kim RB, Schwarz UI. Drug interactions and pharmacogenetic factors contribute to variation
  in apixaban concentration in atrial fibrillation patients in routine care. *Journal of Thrombosis and Thrombolysis*. 2020;49:294-303. doi: 10.1007/s11239-019-01962-2
- 433 33. Ueshima S, Hira D, Kimura Y, Fujii R, Tomitsuka C, Yamane T, Tabuchi Y, Ozawa T, Itoh H,
  434 Ohno S. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult
  435 patients with atrial fibrillation. *British journal of clinical pharmacology*. 2018;84:1301-1312.
  436 doi: 10.1111/bcp.13561
- 437 34. Ueshima S, Hira D, Fujii R, Kimura Y, Tomitsuka C, Yamane T, Tabuchi Y, Ozawa T, Itoh H,
  438 Horie M. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough
  439 concentrations of apixaban in Japanese patients with atrial fibrillation. *Pharmacogenetics*440 *and genomics*. 2017;27:329-336. doi: 10.1097/FPC.00000000000294
- 35. Nakagawa J, Kinjo T, Iizuka M, Ueno K, Tomita H, Niioka T. Impact of gene
  polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of
  rivaroxaban in patients with atrial fibrillation. *Basic & Clinical Pharmacology & Toxicology*.
  2021;128:297-304. doi: 10.1111/bcpt.13488

- Cheng S-T, Wu S, Su C-W, Teng M-S, Hsu L-A, Ko Y-L. Association of ABCG2
  rs2231142-A allele and serum uric acid levels in male and obese individuals in a Han
  Taiwanese population. *Journal of the Formosan Medical Association*. 2017;116:18-23. doi:
  10.1016/j.jfma.2015.12.002
- Kanbay M, Segal M, Afsar B, Kang D-H, Rodriguez-Iturbe B, Johnson RJ. The role of uric
  acid in the pathogenesis of human cardiovascular disease. *Heart*. 2013;99:759-766. doi:
  10.1136/heartjnl-2012-302535
- 452 38. Liu J, Yang W, Li Y, Wei Z, Dan X. ABCG2 rs2231142 variant in hyperuricemia is modified
  453 by SLC2A9 and SLC22A12 polymorphisms and cardiovascular risk factors in an elderly
  454 community-dwelling population. *BMC Medical Genetics*. 2020;21:1-9. doi:
  455 10.1186/s12881-020-0987-4
- 456 39. Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent
  457 risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort
  458 study. *Arthritis Care & Research*. 2009;61:225-232. doi: 10.1002/art.24164
- 40. Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, Mangino M, Albrecht E,
  Wallace C, Farrall M. Meta-analysis of 28,141 individuals identifies common variants
  within five new loci that influence uric acid concentrations. *PLoS genetics*.
  2009;5:e1000504. doi: 10.1371/journal.pgen.1000504
- 463 41. Fu S, Luo L, Ye P, Xiao W. Epidemiological associations between hyperuricemia and
  464 cardiometabolic risk factors: a comprehensive study from Chinese community. *BMC*465 *cardiovascular disorders*. 2015;15:1-5. doi: 10.1186/s12872-015-0116-z
- 466 42. Ee PLR, Kamalakaran S, Tonetti D, He X, Ross DD, Beck WT. Identification of a novel
  467 estrogen response element in the breast cancer resistance protein (ABCG2) gene. *Cancer*468 *research*. 2004;64:1247-1251. doi: 10.1158/0008-5472.can-03-3583
- 469 43. Chang F-W, Fan H-C, Liu J-M, Fan T-P, Jing J, Yang C-L, Hsu R-J. Estrogen enhances the
  470 expression of the multidrug transporter gene ABCG2—increasing drug resistance of breast
  471 cancer cells through estrogen receptors. *International Journal of Molecular Sciences*.
  472 2017;18:163. doi: 10.3390/ijms18010163
- 473 44. Weng L-C, Choi SH, Klarin D, Smith JG, Loh P-R, Chaffin M, Roselli C, Hulme OL,
  474 Lunetta KL, Dupuis J. Heritability of atrial fibrillation. *Circulation: Cardiovascular*475 *Genetics*. 2017;10:e001838. doi: 10.1161/CIRCGENETICS.117.001838
- 476 45. Gudbjartsson DF, Arnar DO, Helgadottir A, Gretarsdottir S, Holm H, Sigurdsson A,
  477 Jonasdottir A, Baker A, Thorleifsson G, Kristjansson K. Variants conferring risk of atrial
  478 fibrillation on chromosome 4q25. *Nature*. 2007;448:353-357. doi: 10.1038/nature06007
- 479 46. Tucker NR, Clauss S, Ellinor PT. Common variation in atrial fibrillation: navigating the path
  480 from genetic association to mechanism. *Cardiovascular research*. 2016;109:493-501. doi:
  481 10.1093/cvr/cvv283
- 482 47. Maharani N, Ting YK, Cheng J, Hasegawa A, Kurata Y, Li P, Nakayama Y, Ninomiya H, 483 Ikeda N, Morikawa K. Molecular mechanisms underlying urate-induced enhancement of 484 Kv1. 5 channel expression in HL-1 atrial myocytes. Circulation Journal.

485 2015;79:2659-2668. doi: 10.1253/circj.CJ-15-0416

- 486 48. Doshi M, Takiue Y, Saito H, Hosoyamada M. The increased protein level of URAT1 was
  487 observed in obesity/metabolic syndrome model mice. *Nucleosides, Nucleotides and Nucleic*488 *Acids*. 2011;30:1290-1294. doi: 10.1080/15257770.2011.603711
- 489 49. Alrajeh K, Roman YM. The frequency of rs2231142 in ABCG2 among Asian subgroups:
  490 implications for personalized rosuvastatin dosing. *Pharmacogenomics*. 2023;24:15-26. doi: 10.2217/pgs-2022-0155
- 492 50. Abdrakhmanov A, Akilzhanova A, Shaimerdinova A, Zhalbinova M, Tuyakova G,
  493 Abildinova S, Albayev R, Ainabekova B, Chinybayeva A, Suleimen Z. The distribution of
  494 the genotypes of ABCB1 and CES1 polymorphisms in Kazakhstani patients with atrial
  495 fibrillation treated with DOAC. *Genes*. 2023;14:1192.
- 496

### 497

# 498 Figure Legends

499

- 500 Figure 1. Flow chart comparing the genetic risk of AF in our study patients and Taiwan biobank's
- 501 healthy subjects.

	Number (%)						
Demographic characteristics	Cases (N=141)	TWB-1 (N=141)					
Gender							
Male	93 (66.0)	93 (66.0)					
Female	48 (34.0)	48 (34.0)					
Age (years)		× ,					
< 40	1 (0.71)	1(0.71)					
40-60	26 (18.44)	26 (18.44)					
> 60	114 (80.45)	114 (80.45)					
Mean $\pm$ SD	66.3±7.8	$66.3 \pm 7.8$					
Median	68.0	68.0					
IQR	63.0-72.0	63.0 - 72.0					
Diabetes							
No	106 (75.2)	116 (82.3)					
Yes	35 (24.8)	25 (17.7)					
Hypertension							
No	91 (64.5)	100 (71.0)					
Yes	50 (35.5)	41 (29.0)					
HbA1c (%)							
Mean $\pm$ SD	$6.2 \pm 1.1$	$6.2 \pm 1.1$					
Median	6.0	5.8					
IQR	5.6-6.6	5.5-6.3					
Serum creatinine (mg/dl)							
Mean $\pm$ SD	$1.2\pm0.7$	$0.8 \pm 0.3$					
Median	1.1	0.8					
IQR	0.8-1.3	0.6-0.9					
TG (mg/dl)							
Mean $\pm$ SD	$102.6 \pm 53.7$	$116.5\pm68.8$					
Median	90.0	99.0					
IQR	66.0-126.0	70.0-134.0					
LDL (mg/dl)							
Mean $\pm$ SD	$78.5\pm30.8$	$114.6\pm28.8$					
Median	73.9	113.0					
IQR	55.8-95.8	95-134					

### **Table 1.** Demographic characteristics of atrial fibrillation and their comparison groups

Abbreviations: TWB, Taiwan Biobank; SD, standard deviation; IQR, interquartile range; HbA1c,
 glycated hemoglobin; TG, triglycerides; LDL, low-density lipoprotein cholesterol.

Genes/SNPs	Genotypes	Cases (N=141)		TWB-1 <sup>a</sup> (N=141)		Crude OR	AOR <sup>b</sup>
		N	(%)	N	(%)	(95% CI)	(95% CI)
	AA	65	46.1	59	41.8	1	1
	AG	63	44.7	66	46.8	0.866 (0.529-1.419)	1.001 (0.531-1.888
ADCD1 ma1128502	GG	13	9.2	16	11.4	0.738 (0.327-1.662)	0.465 (0.168-1.285
ADCD1-181120505	p-trend					0.414	0.271
	AA+AG	128	90.8	125	88.7	1	1
	GG	13	9.2	16	11.3	0.793 (0.367-1.717)	0.465 (0.177-1.224
	TT	48	34.0	48	34.0	1	1
	CT	60	42.6	59	41.8	1.107 (0.594-1.741)	1.190 (0.603-2.349
A D C D 1 41 407 20	CC	33	23.4	34	24.2	0.971 (0.520-1.812)	0.831 (0.369-1.873
<i>ABCB1-</i> rs4148738	p-trend					0.937	0.741
	TT+CT	108	76.6	107	75.9	1	1
	CC	33	23.4	34	24.1	0.962 (0.556-1.664)	0.753 (0.368-1.541
	GG	63	44.7	84	59.6	1	1
	GT	64	45.3	47	33.3	1.816 (1.103-2.989)	1.880 (0.992-3.560
A DCC2 ma 2221142	TT	14	10.0	10	7.1	1.867 (0.778-4.477)	1.791 (0.599-5.356
ADUG2-182251142	p-trend					0.022	0.072
	GG	63	44.7	84	59.6	1	1
	GT+TT	78	55.3	57	40.4	1.825 (1.137-2.927)	1.912(1.035-3.530
	CC	63	44.7	65	46.1	1	1
	TC	63	44.7	62	44.0	1.048 (0.640-1.716)	0.879 (0.468-1.652
CVD2A5 wa7767A6	TT	15	10.6	14	9.9	1.105 (0.493-2.476)	1.941 (0.675-5.578
CIF3A3-F8//0/40	p-trend					0.786	0.502
	CC+TC	126	89.4	127	90.1	1	1
	TT	15	10.6	14	9.9	1.080 (0.501-2.330)	2.058 (0.293-2.085

Table 2. Distribution of *ABCB1*, *ABCG2*, and *CYP3A5* genotypes and odds ratios
 among atrial fibrillation cases and Taiwan biobank controls

 508
 Abbreviations: ABCB1, ATP binding cassette subfamily B member 1; ABCG2, ATP binding

cassette subfamily G member 2; AOR, adjusted odds ratio; *CYP3A5*, cytochrome P450 3A5; TWB,
Taiwan Biobank (https://taiwanview.twbiobank.org.tw/search).

<sup>a</sup> TWB-1 using 1:1 individual matching of age (+/- 1 year) and genders from original 108,829 subjects.

<sup>b</sup> Adjusting by diabetes, hypertension, glycated hemoglobin (HbA1c), serum creatinine,

514 triglycerides (TG) and low-density lipoprotein cholesterol (LDL).

516	Table 3.	Logistic	regression	analysis	with risk estimates	of ABCB1,	ABCG2,	and CYP3A5
		0	0	~				

517 genotypes in Taiwanese female and male atrial fibrillation patients

Genes/SNPs	Cases	TWR-1 <sup>a</sup>	Crude OR	$\Delta OR^{D}(95\%CI)$
(N, %)	(N=141)	(N=141)	(95%CI)	AGK ()5/0CI)
Female (N=48)	(1(-111)	(1(-111)	()0/001)	
ABCB1- rs1128503				
AA	26 (54.2)	19 (39.6)	1	1
AG	20(41.7)	22(47.0)	0.635	0.780 (0.266-2.284)
	20 (41.7)	25 (47.9)	(0.274 - 1.475)	
GG	2(42)	6(125)	0.244	0.106 (0.015-0.724)
_	2 (4.2)	0 (12.5)	(0.044 - 1.342)	
p-trend			0.138	0.047
AA+AG	46 (95.8)	42 (87.5)	1	
GG	2 (4.2)	6 (12.5)	0.304	0.118 (0.018-0.761)
ADCD1 mcA149729	. ,	. ,	(0.038-1.391)	
ABCB1- 154148/38 TT	15(212)	17(25.4)	1	1
	15 (51.5)	17 (33.4)	0.963	1516(0.487-4.721)
CI	17 (35.4)	20 (41.7)	(0.373-2.488)	1.510 (0.407-4.721)
CC	1 ( ( ) ) )	11 (22 0)	1.648	1.757 (0.522-5.918)
	16 (33.3)	11 (22.9)	(0.586 - 4.641)	(111 - 1)
p-trend			0.907	0.349
TT+CT	32 (66.7)	37 (77.1)	1	1
CC	16 (33.3)	11 (22.9)	1.682(0.683-4.144)	1.432 (0.489-4.191)
ABCG2-				
rs2231142	0.6 (5.4.1)	$\mathbf{O}1$	4	1
GG	26 (54.1)	31 (64.6)	l 1 700	$\frac{1}{2000(0.771.5.(11))}$
GI	21 (43.8)	14 (29.2)	1.788 (0.762,4.200)	2.080 (0.771-5.611)
ТТ			(0.702-4.200) 0.307	0 1/13 (0 005 3 803)
11	1 (2.1)	3 (6.2)	(0.039-4.054)	0.145 (0.005-5.005)
p-trend			0.609	0.682
GG	26 (54.1)	31 (64.6)	1	1
GT+TT	22 (45.9)	17 (35.4)	1.543(0.680-3.503)	1.692 (0.631-4.535)
CYP3A5- rs776746		, <i>,</i> , ,	, , , , ,	
CC	23 (47.9)	21 (43.8)	1	1
CT	17 (35 4)	22 (45.8)	0.706	0.714 (0.261-1.951)
	17 (5511)	22 (1010)	(0.297-1.678)	<b>2</b> 202 (0 555 0 500)
11	8 (16.7)	5 (10.4)	1.461	2.303 (0.555-9.599)
n trand			(0.415-5.172)	0.402
p-trend CC+CT	40 (83 3)	13 (80 6)	0.757	0.492
	+0 (05.5)	+3 (0).0)	1 720(0 519-5 696)	2 767
TT	8 (16.7)	5 (10.4)	1.720(0.51) 5.090)	(0.710-10.784)
Male (N=93)				
ABCB1- rs1128503				
AA	39 (41.9)	40 (43.0)	1	1
AG	43 (46.3)	43 (46.2)	1.026	1.235 (0.490-3.115)
	10 (10.0)	10 (1012)	(0.557-1.889)	0.007 (0.015.0.005)
66	11 (11.8)	10 (10.8)	1.128	0.907 (0.215-3.825)
n trand			(0.431-2.930)	0.022
	82 (88 2)	83 (80 2)	0.901	0.922
GG	11 (11.8)	10(10.8)	1 113 (0 449-2 764)	0.792(0.203-3.100)
ABCB1- rs4148738		10 (10.0)	1110 (0117 21/0T)	
TT	33 (35.5)	31 (33.3)	1	1
СТ	12 (16 2)	20 (42 0)	1.036	0.892 (0.333-2.387)
	43 (40.2)	39 (42.0)	(0.538-1.993)	
CC	17 (18 3)	23 (24 7)	0.694	0.274 (0.071-1.053)
	17 (10.3)	23 (2 m)	(0.313-1.539)	

<b>p-trend</b> TT+CT	76 (81.7)	70 (75.3)	0.577 1	0.089 1
CC	17 (18.3)	23 (24.7)	0.681 (0.336-1.379)	0.317 (0.096-1.048)
ABCG2-				
rs2231142				
GG	37 (39.8)	53 (57.0)	1	1
GT	43 (46.2)	33 (35.5)	1.867 (1.006-3.463)	1.718 (0.667-4.425)
TT	13 (14.0)	7 (7.5)	2.660 (0.969-7.306)	4.474 (1.018-19.671)
p-trend			0.021	0.041
GG	37 (39.8)	53 (57.0)	1	1
GT+TT	56 (60.2)	86 (43.0)	2.005 (1.118-3.596)	2.179 (0.894-5.307)
CYP3A5- rs776746			· · ·	
CC	40 (43.0)	44 (47.3)	1	1
СТ	46 (49.5)	40 (43.0)	1.265 (0.693-2.311)	0.756 (0.301-1.896)
TT	7 (7.5)	9 (9.7)	0.856 (0.292-2.511)	0.885 (0.139-5.621)
p-trend	· · ·	· · · ·	0.806	0.646
<b>C</b> C+CT	86 (92.5)	84(90.3)	1	1
TT	7 (7.5)	9 (9.7)	0.760 (0.271-2.133)	1.087 (0.187-6.326)

518 Abbreviations: *ABCB1*, ATP binding cassette subfamily B member 1; *ABCG2*, ATP binding

cassette subfamily G member 2; AOR, adjusted odds ratio; *CYP3A5*, cytochrome P450 3A5; TWB,

520 Taiwan Biobank (https://taiwanview.twbiobank.org.tw/search).

<sup>a</sup> TWB-1 using 1:1 individual matching of age (+/- 1 year) and genders from original 108,829
 subjects.

<sup>b</sup>Adjusting by diabetes, hypertension, glycated hemoglobin (HbA1c), serum creatinine,

524 triglycerides (TG) and low-density lipoprotein cholesterol (LDL).

525



Figure 1. Flow chart comparing the genetic risk of AF in our study patients and Taiwan biobank's healthy subjects.